ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0769

Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial
Abstract Number: 0770

Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies
Abstract Number: 0771

The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Abstract Number: 0772

New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Abstract Number: 0773

Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
Abstract Number: 0774

HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Abstract Number: 0775

The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
Abstract Number: 0776

Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
Abstract Number: 0777

Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study
Abstract Number: 0778

TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
Abstract Number: 0779

Early Experience of Breakthrough COVID-19 Infections in Patients Who Received Pre-exposure Prophylaxis with Tixagevimab/cilgavimab
Abstract Number: 0780

B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients
Abstract Number: 0781

Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Abstract Number: 0782

Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Abstract Number: 0783

Breakthrough SARS-CoV-2 Infections and Predicting Severe Outcomes During Rituximab Therapy in Autoimmune Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].